This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology )
Also on site :
- Rough start dooms SB Foresters
- Top Western firms switching to Chinese AI – WSJ
- Bonita business owner, 85, pleads guilty to $5.8 million Medicare fraud